ticagrelor
a cyclopentyltriazolopyrimidine, inhibitor of platelet activation and aggregation mediated by the P2Y12 ADP-receptor indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction
Ligand Summary
UNII: GLH0314RVC
PubChem: 9871419
Guide to Pharmacology: 1765
ChEMBL: CHEMBL398435
DrugCentral: 4184
LyCHI: 2AXUW7HYJT92
Target Activities
P2RY12
P2Y purinoceptor 12
7 Activities
Items per page:
1 – 7 of 7
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
- | 8.59 | |||||
Ki | 8.7 | |||||
Ki | 7.85 | |||||
Ki | 8.7 | Bioorg. Med. Chem. Lett., (2007) 17:21:6013 | ||||
IC50 | 8.3 | Bioorg. Med. Chem. Lett., (2016) 26:12:2739 | ||||
Ki | 7.85 | J. Med. Chem., (2012) 55:20:8615 | ||||
Ki | 7.85 | NEGATIVE ALLOSTERIC MODULATOR | ||||
SLC29A1
Equilibrative nucleoside transporter 1
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
- | 7.3 | |||||